Learn more

TRANSTECH PHARMA

Overview
  • Total Patents
    31
About

TRANSTECH PHARMA has a total of 31 patent applications. Its first patent ever was published in 2000. It filed its patents most often in Netherlands, Australia and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and biotechnology are ANSORGE SIEGFRIED, BARKOCZY JOZSEF and MEDIVIR UK LTD.

Patent filings per year

Chart showing TRANSTECH PHARMAs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Mjalli Adnan M M 18
#2 Rothlein Robert 12
#3 Webster Jeffrey C 11
#4 Tian Ye Edward 10
#5 Benjamin Eric J 9
#6 Patron Andrew 5
#7 Gopalaswamy Ramesh 4
#8 Ebdrup Soeren 4
#9 Mjalli Adnan M 3
#10 Wysong Christopher L 2

Latest patents

Publication Filing date Title
NL2001556A1 New Receptor for Advanced Glycated Endproducts (RAGE) fusion protein and nucleic acids, useful for treating a RAGE-mediated disorder, e.g. amyloidosis, Alzheimer's disease, cancer, kidney failure, or inflammation
NL2001553A1 New Receptor for Advanced Glycated Endproducts (RAGE) fusion protein and nucleic acids, useful for treating a RAGE-mediated disorder, e.g. amyloidosis, Alzheimer's disease, cancer, kidney failure, or inflammation
NL2001555A1 New Receptor for Advanced Glycated Endproducts (RAGE) fusion protein and nucleic acids, useful for treating a RAGE-mediated disorder, e.g. amyloidosis, Alzheimer's disease, cancer, kidney failure, or inflammation
NL2001554A1 New Receptor for Advanced Glycated Endproducts (RAGE) fusion protein and nucleic acids, useful for treating a RAGE-mediated disorder, e.g. amyloidosis, Alzheimer's disease, cancer, kidney failure, or inflammation
NL2001551A1 New Receptor for Advanced Glycated Endproducts (RAGE) fusion protein and nucleic acids, useful for treating a RAGE-mediated disorder, e.g. amyloidosis, Alzheimer's disease, cancer, kidney failure, or inflammation
NL2001552A1 New Receptor for Advanced Glycated Endproducts (RAGE) fusion protein and nucleic acids, useful for treating a RAGE-mediated disorder, e.g. amyloidosis, Alzheimer's disease, cancer, kidney failure, or inflammation
NL2001557A1 New Receptor for Advanced Glycated Endproducts (RAGE) fusion protein and nucleic acids, useful for treating a RAGE-mediated disorder, e.g. amyloidosis, Alzheimer's disease, cancer, kidney failure, or inflammation
NL2001558A1 New Receptor for Advanced Glycated Endproducts (RAGE) fusion protein and nucleic acids, useful for treating a RAGE-mediated disorder, e.g. amyloidosis, Alzheimer's disease, cancer, kidney failure, or inflammation
CN101356155A Phenoxy acetic acids as PPAR-delta activators
AU5543601A Protein expression system arrays and use in biological screening
MXPA01007869A Method of synthesizing barbituric acid derivatives and their use for the synthesis of chemical libraries.
AU2969800A A method for the synthesis of compounds of formula 1 and derivatives thereof